Cross-over Study on Effect of Lipid Lowering by Acipimox on Cardiac and Skeletal Muscle Mitochondrial Function
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
Accumulation of lipid in skeletal and cardiac muscle has been associated with insulin
resistance and diabetic cardiomyopathy. In skeletal muscle, lipotoxic damage has been
suggested to lead to dysfunction of mitochondria. It remains unknown whether lipotoxicity
leads to mitochondrial dysfunction in heart as well, and if so, whether this also leads to
cardiomyopathy (failure of the heart). Although it has been shown that lipid lowering agents
can improve insulin sensitivity, the effect of lowering free fatty acids on cardiac and
skeletal muscle mitochondrial function remains unknown. In this study the investigators want
to investigate whether lowering cardiac and muscular lipid content will improve mitochondrial
and cellular function in type 2 diabetic patients.
To this end, type 2 diabetic patients and body mass index (BMI)-matched controls will be
included in a blinded cross-over design, in which subjects will receive a lipid lowering
agent (Acipimox) or placebo for 2 weeks in random order. During treatment, diabetes
medication will be stopped. Baseline measurements will be performed prior to the study and
after each treatment to assess cardiac and muscular lipid accumulation, cardiac function,
mitochondrial function and insulin sensitivity.